Factor XI Inhibition to Uncouple Thrombosis From Hemostasis
Key result
Factor XI inhibitors offer promise as hemostasis-sparing anticoagulants by preventing thrombosis without increasing bleeding.
Why the study?
Bleeding is considered an unavoidable side effect of anticoagulant therapy because hemostasis and thrombosis are intricately linked, but emerging evidence suggests factor XI is important for thrombosis while playing a minor role in hemostasis.
Key Points
- To review the distinct enzymatic mechanisms of hemostasis and thrombosis and evaluate whether selective factor XI inhibition can prevent pathological clotting without compromising normal bleeding defense.
- Synthesized molecular, genetic, and clinical evidence contrasting the biological steps of extravascular hemostatic plug formation against intravascular thrombus propagation.
- Evaluated clinical efficacy and safety outcomes from phase 2 trials of factor XI and factor XIa inhibitors alongside registry and trial data for vitamin K antagonists and direct oral anticoagulants.
- Congenital factor XI deficiency confers lower rates of venous thromboembolism and ischemic stroke with mild bleeding tendencies, whereas elevated factor XI levels more than double the risk of venous thromboembolism.
- High-dose direct oral anticoagulant regimens achieve a 50% reduction in intracranial hemorrhage and a 40% reduction in major bleeding versus warfarin, yet fear of bleeding leaves 42% of eligible atrial fibrillation patients untreated.
- Inhibition of factor XI or factor XIa demonstrated efficacy in preventing venous thromboembolism in phase 2 trials of patients undergoing total knee arthroplasty.
Structured PICO
I
Intervention
Factor XI inhibitors
C
Comparator
Current anticoagulants (vitamin K antagonists, direct oral anticoagulants, heparins)
Ask about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“By uncoupling thrombosis and hemostasis, new anticoagulants targeting factor XI (FXI) can result in less bleeding compared with current options. This is feasible because FXI is essential for thrombus expansion but largely unnecessary for hemostasis.”
“FXI is essential for thrombosis but mostly dispensable for hemostasis. In addition to the oral inhibitors of FXIa, parenteral inhibitors are also under development.”
“The concept that FXI inhibition may offer protection against arterial and VTE with modest bleeding risk has found support in animal experiments. The relative minor involvement of FXI in the coagulation pathway triggered by vascular injury through tissue factor-FVII may explain, at least in part, the small impact on the incidence of MI and the relatively mild bleeding tendency associated with FXI deficiency or inhibition.”
Implication
Targeting Factor XI represents a promising hemostasis-sparing anticoagulation strategy that could safely expand treatment to patients currently deemed at too high a risk for bleeding.
Abstract
Hemostasis and thrombosis are believed to be so intricately linked that any strategies that reduce thrombosis will have an inevitable impact on hemostasis. Consequently, bleeding is viewed as an unavoidable side effect of anticoagulant therapy. Emerging evidence suggests that factor XI is important for thrombosis but has a minor role in hemostasis. This information raises the possibility that anticoagulants that target factor XI will be safer than currently available agents. The authors provide a visual representation of the coagulation pathways that distinguishes between the steps involved in thrombosis and hemostasis to explain why factor XI inhibitors may serve as hemostasis-sparing anticoagulants. A safer class of anticoagulants would provide opportunities for treatment of a wider range of patients, including those at high risk for bleeding. Ongoing clinical studies will determine the extent to which factor XI inhibitors attenuate thrombosis without disruption of hemostasis.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Hsu et al. (2021) conducted a review in Thrombosis. Factor XI inhibitors was evaluated. Factor XI inhibitors may serve as hemostasis-sparing anticoagulants by attenuating thrombosis without significantly disrupting hemostasis.